Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jchf.2024.10.015 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
"Pharmacoequity" in Heart Failure Treatment: A Right for Everyone, Not Just a Select Few.
JACC Heart Fail
January 2025
Division of Cardiovascular Medicine, Indiana University, Indianapolis, Indiana, USA. Electronic address:
Paving a Path to Equity in Cardiorenal Care.
Semin Nephrol
March 2024
Institute for Health Equity Research, Department of Population Health, Icahn School of Medicine at Mount Sinai, New York, NY; Barbara T. Murphy Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address:
Cardiorenal syndrome encompasses a dynamic interplay between cardiovascular and kidney disease, and its prevention requires careful examination of multiple predisposing underlying conditions. The unequal distribution of diabetes, heart failure, hypertension, and kidney disease requires special attention because of the influence of these conditions on cardiorenal disease. Despite growing evidence regarding the benefits of disease-modifying agents (e.
View Article and Find Full Text PDFEliminating Health Disparities in Atrial Fibrillation, Heart Failure, and Dyslipidemia: A Path Toward Achieving Pharmacoequity.
Curr Atheroscler Rep
December 2023
Department of Medicine, Duke University School of Medicine, Durham, NC, USA.
Article Synopsis
- * It highlights significant disparities in clinical trial participation, specialist care access, and affordability of medications across various demographic groups.
- * Recommendations for improvement include diversifying clinical trial participants and enhancing access to cardiology care, alongside encouraging guideline-based treatments and systemic reforms for better medication accessibility.
Association of Race and Ethnicity With Oral Anticoagulation and Associated Outcomes in Patients With Atrial Fibrillation: Findings From the Get With The Guidelines-Atrial Fibrillation Registry.
JAMA Cardiol
December 2022
Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina.
Importance: Oral anticoagulation (OAC) is underprescribed in underrepresented racial and ethnic group individuals with atrial fibrillation (AF). Little is known of how differential OAC prescribing relates to inequities in AF outcomes.
Objective: To compare OAC use at discharge and AF-related outcomes by race and ethnicity in the Get With The Guidelines-Atrial Fibrillation (GWTG-AFIB) registry.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!